12月15日 - ** 药物开发商Kyverna Therapeutics KYTX.O股价盘前上涨25.5%至11.02美元
** 该公司 称 (link)，其用于治疗一种罕见运动障碍的实验性细胞疗法miv-cel在一项中期研究中达到了主要目标
** Miv-cel 原名 KYV-101，目前正在僵人综合症患者中进行试验。僵人综合症是一种罕见的自身免疫性疾病，会使肌肉僵硬并引起疼痛性痉挛，通常难以正常行走或移动。
** 这项由 26 人参与的研究表明，该疗法可持续改善患者的活动能力 - KYTX
** 截至 上一交易日收盘，该公司股价已上涨一倍多
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.